Shattuck Labs (STTK) Director Receives 66,300‑Share Option Grant

Rhea-AI Filing Summary

Dr. Mona Ashiya, a director of Shattuck Labs, Inc. (STTK), was granted a stock option on 08/28/2025 allowing purchase of 66,300 shares of common stock at a $0.99 exercise price. The option vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, is exercisable beginning on those vesting dates, and expires on August 28, 2035. The Form 4 reports 66,300 derivative securities beneficially owned following the transaction, filed by one reporting person and signed by an attorney-in-fact on 09/02/2025. An agreement requires the Reporting Person to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for allocation to OrbiMed Private Investments IX, LP.

Positive

• Option grant disclosed: 66,300‑share stock option awarded on 08/28/2025 with a clearly stated $0.99 exercise price.
• Clear vesting schedule: Option vests in three equal annual installments on each of the first three anniversaries of 08/28/2025.
• Full expiry date provided: Option expires on 08/28/2035, giving a defined exercise window.

Negative

• Transfer obligation disclosed: Reporting Person is required to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for provision to OrbiMed Private Investments IX, LP.
• Beneficial ownership complexity: Although 66,300 derivative securities are reported as beneficially owned following the grant, the transfer arrangement affects direct economic control.

Insights

Securities/Corporate Governance Analyst

TL;DR: Director granted a time‑based option for 66,300 shares with an explicit transfer arrangement to OrbiMed entities.

The Form 4 discloses a time‑based stock option awarded on 08/28/2025 with a $0.99 exercise price covering 66,300 shares and a ten‑year term to expiry on 08/28/2035. Vesting is set in three equal annual installments beginning one year from grant, which ties realization of economic benefit to continued service. The filing also documents a contractual obligation to transfer any issued shares or economic proceeds to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for ultimate provision to OrbiMed Private Investments IX, LP, indicating the reporter does not retain unilateral control of proceeds. The report was executed by an attorney‑in‑fact and filed as a single reporting person Form 4.

Equity Compensation Specialist

TL;DR: Standard time‑based option grant with multi‑year vesting and an explicit third‑party transfer arrangement.

The disclosed award is structured as a ten‑year stock option exercisable into 66,300 shares at $0.99, with vesting in three equal annual tranches beginning 08/28/2026. The filing clearly states the option award and the mechanics of vesting and expiry. The obligation to transfer any shares or economic benefit to specified OrbiMed entities is explicitly documented, which affects beneficial ownership and economic receipt despite the option being reported as beneficially owned on a direct basis following the grant. All key dates, quantities, and the transfer agreement are provided in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashiya Mona

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.99	08/28/2025		A		66,300		(1)	08/28/2035	Common Stock	66,300	$0	66,300	D(2)

Explanation of Responses:

1. This option represents the right to purchase a total of 66,300 shares of the Issuer's common stock, and vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, subject to the Reporting Person's continued service to the Issuer.

2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.

	/s/ Andrew R. Neill, Attorney-in-Fact for Dr. Mona Ashiya	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dr. Mona Ashiya report on the Form 4 for STTK?

She reported a stock option grant to purchase 66,300 shares at a $0.99 exercise price dated 08/28/2025.

What is the vesting schedule and expiration for the option in the STTK Form 4?

Vests in three equal annual installments

Does the Form 4 indicate any transfer or third‑party arrangement?

Yes. The Reporting Person is obligated to transfer any securities or economic benefit from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC for allocation to OrbiMed Private Investments IX, LP.

When was the Form 4 filed and who signed it?

The filing was signed by Andrew R. Neill as attorney‑in‑fact for Dr. Mona Ashiya on 09/02/2025.

How many derivative securities are reported as beneficially owned after the transaction?

66,300 derivative securities (the stock option covering 66,300 shares) are reported as beneficially owned following the transaction.